158. Levothyroxine VS Synthroid And TSH

158. Levothyroxine VS Synthroid And TSH



https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2771041#:~:text=Conclusions%20and%20Relevance%20Initiation%20of,effective%20as%20brand%2Dname%20levothyroxine.

Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels
JAMA Netw Open. 2020;3(9):e2017645. doi:10.1001/jamanetworkopen.2020.17645


Quick history lesson- levothyroxine was cleared and approved for generic use in 2004 – until then Synthroid had enjoyed a huge market share. The only market share. They were it and there is soooo much money when you are the only drug on the market and the most prescribed drug on the market—in 2002 the revenue was estimated at 1 billion dollars.

I was alive in 2002 and I can tell you back then 1 billion dollars was a lot of money.

But then 2004 there is now competition, a generic drug.! What does the drug company do? Use some of their small fortune to trash the drug, pay of some doctors to write a paper and later in 2004 there was a paper released by The Endocrine Society released the paper citing concern for the generic drug and the bioavailability.
https://www.endocrine.org/advocacy/position-statements/bioequivalence-of-sodium-levothyroxine

as recent as 2014 the
American Thyroid Association guideline specifically recommends
“Switches between levothyroxine products could
potentially result in variations in the administered dose and
should generally be avoided for that reason”

Meaning don’t have them on brand name synthroid and then switch them to generic. Stay constant!

But todays study wanted to look at the comparative effectiveness of generic vs brand-name levothyroxine in patients initiating therapy for hypothyroidism

4570 patients initiating therapy with thyrotropin levels ranging from 4.5 to 19.9 mIU/L were 1:1 propensity–matched

One group was started on generic levothyroxine and the other group was started on brand-name levothyroxine also known as Synthroid.

As an outcome they looked at three different things
the numbers of individuals who attained a normal thyrotropin level within 3 months,
the clinically meaningful abnormal thyrotropin level within 3 months
the number of people with stable thyrotropin level(s) 3 months AFTER having a normal thyrotropin level

Among 4570 propensity score–matched patients those that received generic levothyroxine had a normal TSH 75.4% of the time and those that got brand-name levothyroxine had a normal TSH 76.9%
And in both groups about 4% of the individuals had a markedly abnormal TSH level (94 [4.1%; 95% CI, 3.4%-5.0%] vs 88 [3.9%; 95% CI, 3.1%-4.7%]; P = .65).

They then took the individuals who had a normal TSH at 3 months and propensity matched those individuals to 3 MORE months and the proportion maintaining normal TSH levels during the next 3 months was similar regardless if you received generic or brand name levothyroxine, 82% vs 83% respectively. (427 [82.6%] vs 433 [83.8%]; P = .62).

Here is the kick in the pants-
Per good RX

Levothyroxine is $4 on good RX
Synthroid is $45

Jaksot(385)

Episode 359: 258. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions

Episode 359: 258. Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions

https://jamanetwork.com/journals/jama/article-abstract/2822097Design, Setting, and Participants  Nested case-control study using population-based linked administrative datasets among adults aged 66 ye...

3 Tammi 20255min

Episode 358: 257. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention

Episode 358: 257. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention

https://www.nejm.org/doi/full/10.1056/NEJMoa2407001ConclusionsNo participants receiving twice-yearly lenacapavir acquired HIV infection. HIV incidence with lenacapavir was significantly lower than bac...

30 Joulu 20246min

Episode 357: 256. Medications for alcohol-use disorder and follow-up after hospitalization

Episode 357: 256. Medications for alcohol-use disorder and follow-up after hospitalization

Allaudeen N et al. Medications for alcohol-use disorder and follow-up after hospitalization for alcohol withdrawal: A multicenter study. J Hosp Med 2024 Dec; 19:1122. (https://doi.org/10.1002/jhm.1345...

27 Joulu 20245min

Episode 356: 255. Real-world use of glucocorticoids for adults hospitalized with community-acquired pneumonia

Episode 356: 255. Real-world use of glucocorticoids for adults hospitalized with community-acquired pneumonia

Real‐world use of glucocorticoids and clinical outcomes in adults hospitalized with community‐acquired pneumonia on medical wards - Malecki - 2024 - Journal of Hospital Medicine - Wiley Online Library...

23 Joulu 20246min

Episode 355: 254. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension

Episode 355: 254. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension

2024 ESC guidelines propose a simple new BP categorization: Non-elevated: less than 120/70 mm Hg in the office (pharmacological treatment is not recommended). Elevated: 120 to 139/70 to 89 mm Hg (phar...

20 Joulu 20248min

Episode 354: 253. Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers

Episode 354: 253. Centralized Colorectal Cancer Screening Outreach in Federally Qualified Health Centers

Question  Does adding centralized mailed fecal immunochemical testing and patient navigation to usual care improve colorectal cancer (CRC) screening in US federally qualified health centers? pragmatic...

18 Joulu 20247min

Episode 353: 252. 2.4 Million to Prevent 4 Hospitalizations!

Episode 353: 252. 2.4 Million to Prevent 4 Hospitalizations!

Packer M et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 2024 Nov 16; [e-pub].https://doi.org/10.1056/NEJMoa2410027  In the industry-funded SUMMIT trial...

13 Joulu 202411min

Episode 352: 251. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease

Episode 352: 251. Safety of Triptans in Patients Who Have or Are at High Risk for Cardiovascular Disease

Wang Z et al. Safety of triptans in patients who have or are at high risk for cardiovascular disease: A target trial emulation. Mayo Clin Proc 2024 Nov; 99:1722. (https://doi.org/10.1016/j.mayocp.2024...

12 Joulu 20246min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
tiedenaiset-podcast
psykopodiaa-podcast
voi-hyvin-meditaatiot-2
rss-pitaisko-erota
meditaatiot-suomeksi
vakeva-elama-viisaampi-mieli-vahvempi-keho
junnut-pelissa
rss-mighty-finland-podcast
puhu-muru
rss-narsisti
rss-kuumilla-aalloilla
rss-uplevel-by-sonja-hannus
rss-pt-paahtio
rss-vapaudu-voimaasi
mielen-puolikkaat
terapiassa
rss-nautinto
aamukahvilla
rss-en-saa-unta